Organoids in Precision Radiotherapy: Methodological Foundations, Tumor‐Specific Evidence, and Translational Roadmaps
Abstract
Radiotherapy remains a cornerstone of cancer treatment, while its efficacy is often limited by tumor radioresistance and the risk of normal tissue toxicity. Conventional preclinical models, including two‐dimensional (2D) cell cultures and murine xenografts, exhibit significant limitations in recapitulating human tumor pathophysiology, thereby impeding the clinical translation of novel radiotherapeutic strategies. Patient‐derived organoids (PDOs) have emerged as transformative three‐dimensional (3D) ex vivo models that recapitulate key aspects of original tumor heterogeneity and are increasingly applied in oncology research.